Clinical Trial

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-03-08; most recent amendment 2025-08-19.
Trial Details
NCT Number NCT05776069
Lead Sponsor Vega Therapeutics, Inc
Conditions Von Willebrand Diseases
Enrollment 116 participants
Start Date 2023-03-16
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-26